SCHEMBL29615769

SCHEMBL29615769

CN1CC2CN(c3ccc4oc5ccccc5c(=O)c4c3)CC2C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 1.00
KCNH2 Q12809 1/20 1.00
MAOA P21397 3/20 0.47
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
GLA P06280 1/20 0.46
CYP3A4 P08684 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
PGAM1 P18669 1/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HSD17B10 Q99714 1/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 2/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
TTR P02766 1/20 0.44
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1791588 1.00 CHRNA7 (1.00) CHRNA7KCNH2MAOAKDM4EALDH1A1
Trifluoroacetic Acid SCHEMBL1792985 0.90 CHRNA7 (0.81) CHRNA7KCNH2MAOANPC1RAB9A
SCHEMBL1797602 0.86 CHRNA7 (0.76) CHRNA7KCNH2KDM4EALDH1A1MAPT
SCHEMBL1795700 0.85 CHRNA7 (0.73) CHRNA7KCNH2MAOAKDM4EALDH1A1
SCHEMBL1794533 0.84 CHRNA7 (0.72) CHRNA7KCNH2KDM4EALDH1A1MAPT
SCHEMBL1794936 0.84 CHRNA7 (0.72) CHRNA7KCNH2KDM4EALDH1A1MAPT
SCHEMBL1797566 0.83 CHRNA7 (0.71) CHRNA7KCNH2KDM4EALDH1A1
Hydrochloric Acid SCHEMBL1794591 0.83 CHRNA7 (0.70) CHRNA7KCNH2KDM4EALDH1A1
SCHEMBL5745966 0.82 CHRNA7 (0.68) CHRNA7KCNH2MAOANPC1RAB9A
SCHEMBL1793910 0.80 CHRNA7 (0.66) CHRNA7KCNH2MAOANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220117989-A1 COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-04-21 US claimed
US-20220117989-A1 COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220117989-A1 COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY EYA3, RB1, ALDH1A2 CHRNA7 323/4885KCNH2 3799/4885MAOA 3894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.